5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), a metabolic enzyme increasingly recognized as a key regulator of adipose tissue function and whole-body energy metabolism. While technically a small molecule rather than a peptide, 5-Amino-1MQ is widely studied alongside metabolic peptides due to its effects on fat metabolism, cellular energy balance, and NAD+ homeostasis. NNMT inhibition represents a novel approach to metabolic regulation distinct from incretin-based or growth hormone-based pathways.
NNMT Biology
Nicotinamide N-methyltransferase catalyzes the methylation of nicotinamide (vitamin B3) to 1-methylnicotinamide (1-MNA), using S-adenosylmethionine (SAM) as the methyl donor. This reaction has two important metabolic consequences: it reduces the availability of nicotinamide for NAD+ biosynthesis (the salvage pathway), and it consumes SAM, affecting methylation capacity across the cell.
NNMT expression is elevated in white adipose tissue of obese individuals and in animal models of diet-induced obesity. Studies have demonstrated a causal relationship: NNMT knockdown in adipose tissue reduces body weight and improves insulin sensitivity in obese mice, while NNMT overexpression promotes adiposity. The enzyme appears to function as a metabolic switch that, when overactive, shifts adipocytes toward energy storage rather than expenditure.
5-Amino-1MQ Mechanism
5-Amino-1MQ is a cell-permeable, selective NNMT inhibitor with an IC50 in the low micromolar range. It binds the substrate (nicotinamide) binding site of NNMT, preventing the methylation reaction. By blocking NNMT, 5-Amino-1MQ produces several metabolic effects in adipocytes.
First, it increases intracellular NAD+ levels by preserving nicotinamide for the NAD+ salvage pathway. NAD+ is a critical cofactor for sirtuins (SIRT1-7), mitochondrial electron transport, and other metabolic enzymes. Elevated NAD+ promotes mitochondrial function, oxidative metabolism, and cellular energy expenditure. Second, NNMT inhibition increases SAM availability, enhancing methylation capacity for histone and DNA methylation—epigenetic modifications that can shift gene expression toward a more metabolically active phenotype.
In adipocyte culture studies, 5-Amino-1MQ treatment reduced lipid accumulation, decreased adipocyte size, increased oxygen consumption rate (a marker of mitochondrial activity), and reduced expression of adipogenic transcription factors (PPARgamma, C/EBPalpha). These effects suggest a shift from lipid storage toward lipid oxidation.
Preclinical Evidence
In diet-induced obese (DIO) mouse models, 5-Amino-1MQ administration produced significant reductions in body weight, fat mass, and adipocyte cell size without affecting food intake. The compound improved glucose tolerance and insulin sensitivity, reduced circulating cholesterol and triglyceride levels, and decreased inflammatory markers in adipose tissue.
Notably, 5-Amino-1MQ did not affect lean body mass, suggesting its effects are specific to adipose tissue metabolism. This selectivity likely reflects the high NNMT expression in white adipose tissue compared to other tissues. Muscle function and organ weights were unaffected in preclinical studies.
Connection to NAD+ Biology
NNMT inhibition connects to the broader field of NAD+ biology and aging research. NAD+ levels decline with age, and this decline is implicated in mitochondrial dysfunction, reduced sirtuin activity, and metabolic deterioration. Strategies to boost NAD+ (including NMN, NR supplementation, and NNMT inhibition) are being investigated for both metabolic and longevity benefits. 5-Amino-1MQ offers a complementary approach to NAD+ elevation by reducing NAD+ precursor diversion rather than supplementing precursors directly. See our NAD+ Peptide Research overview for related approaches.
Research Status and Limitations
5-Amino-1MQ remains in the preclinical research stage. Pharmacokinetic data in humans is lacking, and optimal dosing, bioavailability, tissue distribution, and long-term safety have not been established through clinical trials. The selectivity of 5-Amino-1MQ for NNMT over other methyltransferases requires ongoing characterization to assess potential off-target effects. Additionally, the consequences of chronic NNMT inhibition on 1-MNA-dependent pathways (1-MNA itself has anti-inflammatory and vascular effects) need investigation.
Frequently Asked Questions
What is 5-Amino-1MQ?
5-Amino-1MQ is a small molecule inhibitor of NNMT, an enzyme involved in cellular energy metabolism and fat storage. It increases NAD+ availability and shifts adipocyte metabolism toward energy expenditure.
How does NNMT inhibition affect metabolism?
Inhibiting NNMT increases SAM and NAD+ availability, shifts adipocyte metabolism toward energy expenditure, and reduces lipid accumulation by preserving nicotinamide for the NAD+ salvage pathway.
Is 5-Amino-1MQ a peptide?
No, it is a small molecule quinolinium compound. However, it is commonly studied alongside metabolic peptides due to its effects on energy metabolism and fat regulation.